Name: ANAVEX LIFE SCIENCES CORP (AVXL) Stock
Brand: ANAVEX LIFE SCIENCES CORP
Rating: 3.5 (3 reviews)

AVXL Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: Chartmill - Mentions: CDTX SRRK KXIN PGEN ...

Top movers analysis one hour before the close of the markets on 2025-11-14: top gainers and losers in today's session.

9 days ago - By: Chartmill - Mentions: CDTX BCAB NVVE NVNO ...

Which stocks are moving on Friday?

4 days ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL

4 days ago - By: Anavex Life Sciences Corp.

Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference

4 days ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL

5 days ago - By: Anavex Life Sciences Corp.

Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025

6 days ago - By: Stocktwits

Anavex Retail Traders See Silver Lining In EMA Committee Postpones Alzheimer’s Drug Verdict: Delay 'Actually A Positive Sign'

9 days ago - By: Benzinga - Mentions: PTN ZYXI CDTX CMND ...

12 Health Care Stocks Moving In Friday's Intraday Session

9 days ago - By: Chartmill - Mentions: CDTX AVDL SRRK KXIN ...

Let's uncover which stocks are experiencing notable gaps during today's session.

9 days ago - By: Chartmill - Mentions: CDTX NVVE NVNO GWH ...

Discover the top movers in Friday's pre-market session.

9 days ago - By: Benzinga - Mentions: VSTM TSSI SEI RCAT ...

Red Cat Posts Downbeat Q3 Results, Joins StubHub, WhiteFiber And Other Big Stocks Moving Lower In Friday's Pre-Market Session

9 days ago - By: Anavex Life Sciences Corp.

Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease

9 days ago - By: Stocktwits

AVXL Shares Slump Pre-market After EMA Committee Fails To Recommend Approval For Alzheimer’s Drug

9 days ago - By: Stocktwits

Anavex Stock Just Logged Its Worst Selloff In 2 Years — What Does EMA’s Oral Explanation Week Mean For Its Alzheimer’s Drug?

12 days ago - By: Stocktwits - Mentions: IWMW EAOR

AVXL Stock Draws Retail Attention Ahead Of Company’s Meeting With EMA Committee

25 days ago - By: Anavex Life Sciences Corp.

Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group

a month ago - By: Stocktwits

Anavex Life Sciences Stock Sparks Retail Banter On Hopes Of EMA Conditional Nod For Alzheimer's Drug, Big Pharma Tie-Up

a month ago - By: Anavex Life Sciences Corp.

Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’

2 months ago - By: Stocktwits - Mentions: EAOR ITOT

Anavex Life Sciences Stock Just Shot Up 7% Today – Here’s An Important Update

2 months ago - By: Anavex Life Sciences Corp.

Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program

2 months ago - By: Anavex Life Sciences Corp.

Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

2 months ago - By: Anavex Life Sciences Corp.

Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease Trial

2 months ago - By: Stocktwits - Mentions: EAOR VTWG

Anavex Life Sciences Stock Rises After Experimental Alzheimer’s Drug Slows Cognitive Decline In Study

2 months ago - By: Anavex Life Sciences Corp.

Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial

3 months ago - By: Anavex Life Sciences Corp.

Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025

3 months ago - By: Anavex Life Sciences Corp.

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine

3 months ago - By: Anavex Life Sciences Corp.

ANAVEX LIFE SCIENCES CORP (AVXL) Stock News

AVXL Latest News, Press Relases and Analysis

Top movers analysis one hour before the close of the markets on 2025-11-14: top gainers and losers in today's session.

Which stocks are moving on Friday?

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL

Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL

Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025

Anavex Retail Traders See Silver Lining In EMA Committee Postpones Alzheimer’s Drug Verdict: Delay 'Actually A Positive Sign'

12 Health Care Stocks Moving In Friday's Intraday Session

Let's uncover which stocks are experiencing notable gaps during today's session.

Discover the top movers in Friday's pre-market session.

Red Cat Posts Downbeat Q3 Results, Joins StubHub, WhiteFiber And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease

AVXL Shares Slump Pre-market After EMA Committee Fails To Recommend Approval For Alzheimer’s Drug

Anavex Stock Just Logged Its Worst Selloff In 2 Years — What Does EMA’s Oral Explanation Week Mean For Its Alzheimer’s Drug?

AVXL Stock Draws Retail Attention Ahead Of Company’s Meeting With EMA Committee

Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group

Anavex Life Sciences Stock Sparks Retail Banter On Hopes Of EMA Conditional Nod For Alzheimer's Drug, Big Pharma Tie-Up

Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’

Anavex Life Sciences Stock Just Shot Up 7% Today – Here’s An Important Update

Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program

Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease Trial

Anavex Life Sciences Stock Rises After Experimental Alzheimer’s Drug Slows Cognitive Decline In Study

Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial

Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine

Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer’s Disease